The BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK inhibitor (MEKi) trametinib was approved for stage III BRAF V600E/K mutated melanoma patients after complete resection of metastases [5] by EMA and Swissmedic in August 2018. This evidence concerns the gene BRAF and melanoma.